神经母细胞瘤研究前沿及思考  

Research frontiers and reflections on neuroblastoma

作　　者：普佳睿[1] 童强松[1] Jiarui Pu;Qiangsong Tong(Department of Pediatric Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院小儿外科,武汉市430022

出　　处：《中国肿瘤临床》2023年第9期448-452,共5页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:81772967、81874085和82072801)资助。

摘　　要：神经母细胞瘤(neuroblastoma,NB)是儿童最常见的颅内实体肿瘤,发现时常常已是晚期,易发生转移,高危NB患儿即使接受高强度治疗,仍可出现复发或转移,治疗效果差。目前NB的发病机制及治疗等已成为儿童实体恶性肿瘤研究的热点、难点。近年来,随着单细胞测序等各种技术手段的进步,NB的发病机制、治疗手段等相关研究取得了诸多进展。本文将对近年来NB的研究进展进行文献综述,阐述了NB的起源、分子遗传学调控机制及免疫学调控机制研究成果,并介绍NB单克隆抗体、肿瘤疫苗、过继细胞疗法及小分子抑制剂的最新进展。Neuroblastoma is the most common intracranial solid tumor in children.It is often found at an advanced stage and is prone to metastasis.Even when high-risk patients receive high-intensity treatment,it can still recur or metastasize,and the prognosis is poor.Currently,the pathogenesis and treatment of neuroblastoma have become a research focus and are recognized as difficult issues in the study of pediatric solid tumors.In recent years,with the progress of single-cell sequencing and other techniques,many advances have been made in research on the pathogenesis and management of neuroblastoma.This article reviews the recent progress of research on neuroblastoma,including its origin and molecular,genetic,and immunological regulation mechanisms,and discusses the latest advances in research on monoclonal antibodies,tumor vaccines,adoptive cell therapy,and small-molecule inhibitors of neuroblastoma.

关 键 词：神经母细胞瘤 发病机制 免疫治疗 靶向治疗 研究前沿 

分 类 号：R739.41[医药卫生—肿瘤]